(PODD) Insulet - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 10.709m USD | Total Return: -51.8% in 12m

Insulin Pumps, Drug Delivery, Medical Devices
Total Rating 59
Safety 80
Buy Signal -0.06
Medical Devices
Industry Rotation: +4.9
Market Cap: 10.7B
Avg Turnover: 231M
Risk 3d forecast
Volatility55.5%
VaR 5th Pctl9.14%
VaR vs Median-0.06%
Reward TTM
Sharpe Ratio-1.93
Rel. Str. IBD0.7
Rel. Str. Peer Group1.9
Character TTM
Beta0.644
Beta Downside0.723
Hurst Exponent0.400
Drawdowns 3y
Max DD58.21%
CAGR/Max DD-0.30
CAGR/Mean DD-0.74
EPS (Earnings per Share) EPS (Earnings per Share) of PODD over the last years for every Quarter: "2021-03": 0, "2021-06": 0.23, "2021-09": 0.18, "2021-12": 0.42, "2022-03": 0.4, "2022-06": -0.5, "2022-09": 0.35, "2022-12": 0.24, "2023-03": 0.23, "2023-06": 0.38, "2023-09": 0.71, "2023-12": 1.4, "2024-03": 0.73, "2024-06": 0.55, "2024-09": 0.9, "2024-12": 1.15, "2025-03": 1.02, "2025-06": 1.17, "2025-09": 1.24, "2025-12": 1.44, "2026-03": 1.42,
EPS CAGR: 55.73%
EPS Trend: 89.9%
Last SUE: 1.68
Qual. Beats: 1
Revenue Revenue of PODD over the last years for every Quarter: 2021-03: 252.3, 2021-06: 263.2, 2021-09: 275.6, 2021-12: 307.7, 2022-03: 295.4, 2022-06: 299.4, 2022-09: 340.8, 2022-12: 369.7, 2023-03: 358.1, 2023-06: 396.5, 2023-09: 432.7, 2023-12: 509.8, 2024-03: 441.7, 2024-06: 488.5, 2024-09: 543.9, 2024-12: 597.5, 2025-03: 569, 2025-06: 649.1, 2025-09: 706.3, 2025-12: 783.8, 2026-03: 761.7,
Rev. CAGR: 27.20%
Rev. Trend: 99.8%
Last SUE: 4.00
Qual. Beats: 17

Warnings

Below Avwap Earnings

Tailwinds

Garp

Description: PODD Insulet

Insulet Corporation (PODD) specializes in the development and manufacture of tubeless insulin delivery systems, primarily through its Omnipod product line. Its flagship offerings, including the Omnipod 5 and Omnipod DASH, utilize Bluetooth-enabled pods and integrated algorithms to automate insulin delivery via synchronization with continuous glucose monitors. Beyond diabetes care, the company leverages its delivery technology for non-insulin applications, such as the Neulasta Onpro kit for oncology patients.

The company operates within the high-growth medical device sector, characterized by high barriers to entry due to stringent regulatory requirements and complex intellectual property landscapes. Insulet’s business model focuses on a recurring revenue stream, as the disposable pods must be replaced every few days, creating a consistent demand cycle compared to traditional durable medical equipment. Distribution is managed through both direct pharmacy channels and independent distributors to reach global markets.

Investors may find ValueRay useful for deeper analysis of the companys valuation and competitive positioning. Headquartered in Acton, Massachusetts, Insulet remains a key player in the transition toward automated, wearable healthcare technology.

Headlines to Watch Out For
  • Omnipod 5 adoption and international market expansion drive recurring revenue growth
  • Competitive pressure from GLP-1 medications impacts long-term insulin demand sentiment
  • Pharmacy channel transition improves gross margins and lowers patient acquisition costs
  • Integration with diverse continuous glucose monitors expands the addressable user base
  • Regulatory approval timelines for expanded indications influence future market share gains
Piotroski VR-10 (Strict) 9.5
Net Income: 302.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.86 > 1.0
NWC/Revenue: 35.23% < 20% (prev 81.25%; Δ -46.02% < -1%)
CFO/TA 0.21 > 3% & CFO 619.3m > Net Income 302.8m
Net Debt (472.3m) to EBITDA (561.5m): 0.84 < 3
Current Ratio: 2.49 > 1.5 & < 3
Outstanding Shares: last quarter (70.2m) vs 12m ago -5.27% < -2%
Gross Margin: 71.01% > 18% (prev 0.70%; Δ 7.03k% > 0.5%)
Asset Turnover: 89.20% > 50% (prev 62.52%; Δ 26.68% > 0%)
Interest Coverage Ratio: 6.62 > 6 (EBITDA TTM 561.5m / Interest Expense TTM 69.5m)
Altman Z'' 3.85
A: 0.34 (Total Current Assets 1.71b - Total Current Liabilities 687.5m) / Total Assets 2.99b
B: 0.13 (Retained Earnings 378.5m / Total Assets 2.99b)
C: 0.14 (EBIT TTM 460.4m / Avg Total Assets 3.25b)
D: 0.23 (Book Value of Equity 384.2m / Total Liabilities 1.68b)
Altman-Z'' = 3.85 = AA
Beneish M -2.85
DSRI: 1.03 (Receivables 544.7m/402.3m, Revenue 2.90b/2.20b)
GMI: 0.99 (GM 71.01% / 70.39%)
AQI: 1.07 (AQ_t 0.15 / AQ_t-1 0.14)
SGI: 1.32 (Revenue 2.90b / 2.20b)
TATA: -0.11 (NI 302.8m - CFO 619.3m) / TA 2.99b)
Beneish M = -2.85 (Cap -4..+1) = A
What is the price of PODD shares?

As of May 23, 2026, the stock is trading at USD 156.89 with a total of 915,469 shares traded.
Over the past week, the price has changed by +5.03%, over one month by -20.01%, over three months by -37.90% and over the past year by -51.75%.

Is PODD a buy, sell or hold?

Insulet has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PODD.

  • StrongBuy: 14
  • Buy: 6
  • Hold: 2
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the PODD price?
Analysts Target Price 246.8 57.3%
Insulet (PODD) - Fundamental Data Overview as of 21 May 2026
P/E Trailing = 36.1238
P/E Forward = 23.4742
P/S = 3.6917
P/B = 7.8352
P/EG = 1.1381
Revenue TTM = 2.90b USD
EBIT TTM = 460.4m USD
EBITDA TTM = 561.5m USD
Long Term Debt = 929.5m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 952.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.60m
Net Debt = 472.3m USD (calculated: Debt 952.7m - CCE 480.4m)
Enterprise Value = 11.2b USD (10.7b + Debt 952.7m - CCE 480.4m)
Interest Coverage Ratio = 6.62 (Ebit TTM 460.4m / Interest Expense TTM 69.5m)
EV/FCF = 27.13x (Enterprise Value 11.2b / FCF TTM 412.2m)
FCF Yield = 3.69% (FCF TTM 412.2m / Enterprise Value 11.2b)
FCF Margin = 14.21% (FCF TTM 412.2m / Revenue TTM 2.90b)
Net Margin = 10.44% (Net Income TTM 302.8m / Revenue TTM 2.90b)
Gross Margin = 71.01% ((Revenue TTM 2.90b - Cost of Revenue TTM 840.9m) / Revenue TTM)
Gross Margin QoQ = 69.46% (prev 72.54%)
Tobins Q-Ratio = 3.74 (Enterprise Value 11.2b / Total Assets 2.99b)
Interest Expense / Debt = 7.30% (Interest Expense 69.5m / Debt 952.7m)
Taxrate = 19.38% (21.9m / 113.0m)
NOPAT = 371.2m (EBIT 460.4m * (1 - 19.38%))
Current Ratio = 2.49 (Total Current Assets 1.71b / Total Current Liabilities 687.5m)
Debt / Equity = 0.73 (Debt 952.7m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.84 (Net Debt 472.3m / EBITDA 561.5m)
Debt / FCF = 1.15 (Net Debt 472.3m / FCF TTM 412.2m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.31% (Net Income 302.8m / Total Assets 2.99b)
RoE = 21.38% (Net Income TTM 302.8m / Total Stockholder Equity 1.42b)
RoCE = 19.63% (EBIT 460.4m / Capital Employed (Equity 1.42b + L.T.Debt 929.5m))
RoIC = 16.01% (NOPAT 371.2m / Invested Capital 2.32b)
WACC = 8.06% (E(10.7b)/V(11.7b) * Re(8.25%) + D(952.7m)/V(11.7b) * Rd(7.30%) * (1-Tc(0.19)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.22 | Cagr: 0.22%
[DCF] Terminal Value 77.97% ; FCFF base≈359.0m ; Y1≈411.6m ; Y5≈605.7m
[DCF] Fair Price = 124.8 (EV 9.12b - Net Debt 472.3m = Equity 8.64b / Shares 69.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 89.89 | EPS CAGR: 55.73% | SUE: 1.68 | # QB: 1
Revenue Correlation: 99.82 | Revenue CAGR: 27.20% | SUE: 4.0 | # QB: 17
EPS current Quarter (2026-06-30): EPS=1.44 | Chg30d=+0.22% | Revisions=+0% | Analysts=21
EPS next Quarter (2026-09-30): EPS=1.64 | Chg30d=-2.04% | Revisions=-65% | Analysts=21
EPS current Year (2026-12-31): EPS=6.46 | Chg30d=+1.86% | Revisions=+84% | GrowthEPS=+30.0% | GrowthRev=+22.8%
EPS next Year (2027-12-31): EPS=8.05 | Chg30d=-0.32% | Revisions=+20% | GrowthEPS=+24.6% | GrowthRev=+18.7%
[Analyst] Revisions Ratio: +84%